baber/WOPTO huggingface dataset:
Patent NZ-575804-A (NZ)
Title: Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
Inventor: KARSENTY GERARD
IPC: A61K38/00
Filed: 2007-09-13
Abstract: Disclosed is the use of uncarboxylated/undercarboxylated osteocalcin, or a biologically active fragment thereof, for the manufacture of a medicament for the therapeutic or prophylactic treatment of a disorder selected from the group consisting of diabetes, metabolic syndrome, glucose intolerance, a vascular disorder, atherosclerosis, and obesity in a mammal, wherein the uncarboxylated/undercarboxylated osteocalcin or the biologically active fragment thereof is capable of causing at least one effect selected from the group consisting of increasing pancreatic beta-cell proliferation, increasing insulin production, increasing insulin secretion, increasing insulin sensitivity, increasing glucose tolerance, decreasing weight gain, decreasing fat mass, weight loss, increasing serum adiponectin, a reduction of oxidized phospholipids, a regression of atherosclerotic plaques, a decrease in inflammatory protein biosynthesis, a reduction in plasma cholesterol, a reduction in vascular smooth muscle cell (VSMC) proliferation and number, a decrease in the thickness of arterial plaque, a reduction in clinical events such as heart attack, angina, or stroke, and a decrease in hypertension.
Patent NZ-581604-A (NZ)
Title: Water-tight and air-tight aluminium or aluminium-plastic medicine packet
Inventor: CAIRNS GRAHAM
IPC: A61K9/00
Filed: 2008-05-14
Abstract: Disclosed is a water- and oxygen-occlusive pack formed of aluminium or aluminium-plastics laminate, the pack enclosing an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof.
Patent NZ-581916-A (NZ)
Title: Vibration absorber, and vibration control structure using the same
Inventor: MOCHIMARU MASAMI
IPC: F16F9/32
Filed: 2003-02-07
Abstract: A building damper 7 includes a control element 142 for controlling an increase or decrease in the internal pressure of the viscous or viscoelastic body 26 in the extension or retraction of the inserted portion of the inner elongated body 22 in the axial direction with respect to the interior of the outer elongated body 21. The control element has a flexible partition wall 142 partitioning a hollow portion of at least one of the inner and outer elongate bodies into a chamber with a viscous or viscoelastic body filled therein and an air chamber 146, and for increasing of decreasing the volume of the chamber by the increase or decrease of the internal pressure of the viscous or viscoelastic body. (62) Divided Out of 569348
Patent NZ-582752-A (NZ)
Title: Combined method and kit for the sequential measurement of (1) the enzymatically active fraction via siefed and (2) the total amount of an enzyme via elisa
Inventor: SERTEYN DIDIER
IPC: C12Q1/28
Filed: 2008-06-02
Abstract: Disclosed is a kit for performing a sequential "Specific Immunological Extraction Followed by Enzymatic Detection" (SIEFED)- "Enzyme-Linked Immuno Sorbent Assay" (ELISA) measuring an activation status of an enzyme or cells which may release the said enzyme in a biological sample obtained from a mammal or measuring effects of synthethized or natural compounds on the said enzyme, and which comprises: - one solid support surface, - a primary antibody or hypervariable portion thereof, both specific of the said enzyme and being fixed upon said solid support surface, - a suitable substrate to be transformed by the enzyme into a visible reaction product, - a secondary antibody or a hypervariable portion thereof both being specific of the said enzyme, wherein the first antibody and the second antibody do not cross react between them, - reagents for a detection of a complex of same said primary antibody -said enzyme -said secondary antibody fixed on the same said solid support surface, and - a sample of the said pure enzyme with a determined enzymatic activity and a determined total quantity, to be used for establishing SIEFED and ELISA reference curves. Also disclosed is an in vitro method for a measurement of an enzymatically active fraction and a total amount of an enzyme in a same complex biological sample, said method being a SIEFED method followed by an ELISA method, this "combined SIEFED-ELISA" method being performed sequentially with the same primary antibody or hypervariable portion thereof both being specific of the said enzyme, which is fixed upon the same solid support and wherein the SIEFED method and ELISA method are performed sequentially upon the same solid support using the same primary antibody.
Patent NZ-583212-A (NZ)
Title: Container and lid configured to pierce a flexible bag
Inventor: PRYOR RICHARD
IPC: B65D17/44
Filed: 2010-02-09
Abstract: Disclosed is a container for dispensing liquid from a flexible bag. The container includes a clamp to secure an ear of the bag to the container rim, and a lid with a piercing member which pierces the bag adjacent the clamp as the lid is closed. The piercing member is in communication with an outlet aperture so as to allow liquid to flow from the bag.
Patent NZ-583533-A (NZ)
Title: Closure/stopper with multi-layer film affixed thereto
Inventor: MILLER DARRELL JAMES
IPC: B65D39/00
Filed: 2008-09-11
Abstract: Disclosed is a stopper or closure (20) for a product retaining container constructed for being inserted and securely retained in a portal forming neck of the container for sealingly closing the container and retaining the products therein. A multi-layer film (16, 18) is affixed to the terminating end of a closure/stopper, with the multi-layer film being constructed for promoting the transfer of all of the desirable gases, chemicals, and/or compounds while preventing the transfer of undesirable gases, chemicals, and/or compounds. Wine sealed in the wine bottle by the closure/stopper of the present invention is assured of possessing a long storage life, while also having the flavour, bouquet, taste, and quality desired for the wine fully maintained.
Patent NZ-586947-A (NZ)
Title: Modified leptin polypeptides and their uses
Inventor: KRAYNOV VADIM
IPC: C07H21/04
Filed: 2009-02-05
Abstract: Disclosed is a leptin polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4, wherein one or more amino acid(s) selected from amino acids at positions 46, 108 and 111 of SEQ ID NO: 2 or a corresponding amino acid(s) of SEQ ID NO: 4 is/are a non-naturally encoded amino acid (NEAA) by virtue of comprising a poly(ethylene glycol) moiety.
Patent NZ-594291-A (NZ)
Title: Stereoselective method for synthesis of (1s,2r)-milnacipran
Inventor: NICOLAS MARC
IPC: C07C231/18
Filed: 2010-01-29
Abstract: Disclosed is an enantioselective method for preparing a pharmaceutically acceptable acid addition salt of (1S,2R)-milnacipran of Formula (I), which does not involve the reagent sodium azide, comprising: 1) The reaction of phenylacetonitrile and epichlorohydrin in the presence of a base 2) Reaction of the product of step 1 with diethylamine in the presence of a Lewis acid-amine complex 3) Reaction of the product of step 2 with thionyl chloride to generate the chloride precursor to the compound of Formula (I) 4) Reaction of the product of step 3 with a phthalimide salt 5) Hydrolysis of the product of step 4 to generate (1S,2R)-milnacipran 6) Preparation of the acid addition salt of (1S,2R)-milnacipran
Patent NZ-594671-A (NZ)
Title: Compositions and methods for inhibiting the agglomeration of hydrates in a process
Inventor: ACOSTA ERICK J
IPC: C07D241/04
Filed: 2010-03-04
Abstract: Patent No. 594671 Disclosed is a composition comprising formula I and optionally salts thereof: where R1 is CnH2n+1, wherein n=0 to 12; benzyl; or H; where R2 is a C4 to C22 alkyl; where R3 is CnH2n+1, wherein n=0 to 12; benzyl; or H; where X- is a sulfate and wherein X- is only present when both R1 and R3 are present; where Y = (CH2)n, wherein n is 1 to 8; and wherein R3 and R1 cannot be hydrogen at the same time.
Patent NZ-594796-A (NZ)
Title: Generation of split billing records for an end-user device's usage of a wireless data network
Inventor: RALEIGH GREGORY G
IPC: H04L12/14
Filed: 2010-01-27
Abstract: A wireless data network access accounting system, comprises a charging data record (COR) feed configured to obtain one or more CORs from one or more COR sources, wherein each COR comprises information identifying one or more device activities, indicates a usage amount associated with the one or more device activities, and is associated with a particular end-user device configured to send or receive data over a wireless data network; memory configured to store the one or more CORs, and one or more allocation rules configured to assist in generating a plurality of split billing records, each of the plurality of split billing records for assisting an operator of the wireless data network in billing an entity for usage of the wireless data network associated with the one or more device activities by the particular end-user device; and a rules engine configured to generate, using the one or more allocation rules and at least one of the one or more CORs, a first split billing record of the plurality of split billing records and a second split billing record of the plurality of split billing records, the first split billing record configured to assist the operator of the wireless data network in billing a first entity for at least a first portion of the usage of the wireless data network associated with the one or more device activities indicated by the at least one of the one or more CORs, the first entity being a service sponsor, the second split billing record configured to assist the operator of the wireless data network in billing a second entity for at least a second portion of the usage of the wireless data network associated with the one or more device activities indicated by the at least one of the one or more CORs, the first entity being an entity other than a user of the particular end-user device and other than the operator of the wireless data network.
Patent NZ-594808-A (NZ)
Title: Rigid boat convertible into a hinged shelter
Inventor: MURPHY BRIAN CHARLES
IPC: B63B7/00
Filed: 2012-08-22
Abstract: A non-inflatable boat which consists of at least two fully separable parts and which includes means for securing said parts 5 together such that at least two of said parts may be releasably hinged together so as to be inclined at an angle to each other to form a shelter, and both or all of said parts may be rigidly releasably secured together to form a boat.
Patent NZ-596300-A (NZ)
Title: Fviii-derived peptides
Inventor: WRAITH DAVID
IPC: A61K38/37
Filed: 2010-05-17
Abstract: NZ 596300 Disclosed is a peptide comprising the FVIII-derived sequence PRCLTRYYSSFVNME with one or more of the following modifications: removal of one or more hydophobic amino acid(s); replacement of one or more hydrophobic amino acid(s) with charged hydrophilic amino acid(s); and insertion of a charged amino acid at one or both terminus(i) wherein the modified peptide is capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell.
Patent NZ-596945-A (NZ)
Title: Low dose methods for treating disorders in which TNFalpha activity is detrimental
Inventor: KAMEN ROBERT
IPC: A61K/
Filed: 2003-10-24
Abstract: NZ 596945 Disclosed is the use of a human anti-TNF-alpha antibody, which is either D2E7 or a human anti-TNF-alpha antibody with equivalent properties to D2E7 which dissociates from human TNF-alpha with a Kd of 1 x 10-8 M or less and a koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralises human TNF-alpha cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less, for manufacture of a medicament for the treatment of rheumatoid arthritis in a subject, wherein the medicament is to be administered in a low dose of 0.01-0.11 mg anti-TNF-alpha antibody/kg subject in combination with methotrexate.
Patent NZ-597717-A (NZ)
Title: Composition containing clothianidin or dinotefuran that prevents damage to trees by harmful insects and a prevention method thereof
Inventor: WATANABE KUNITOSHI
IPC: A01N25/00
Filed: 2005-03-10
Abstract: Disclosed is a method for preventing damage to trees caused by harmful insects by injecting into a tree trunk a composition containing a neonicotinoid-based insecticide selected from clothianidin and dinotefuran, a solvent miscible with water and a surfactant, wherein the surfactant contains at least one type selected from the group consisting of polyoxyethylene hardened caster oils and polyoxyethylene styryl phenyl ethers.
Patent NZ-598009-A (NZ)
Title: Genetic markers associated with risk of diabetes mellitus
Inventor: KONG AUGUSTINE
IPC: A61P3/08
Filed: 2010-07-09
Abstract: 598009 Disclosed is a method of determining a susceptibility to type 2 diabetes in a human individual, the method comprising: obtaining nucleic acid sequence data from a nucleic acid sample or a genotype dataset about a human individual identifying at least one allele of at least one polymorphic marker, and determining a susceptibility to type 2 diabetes from the sequence data, wherein the at least one polymorphic marker is selected from the group consisting of rs2334499, and markers in linkage disequilibrium therewith, wherein linkage disequilibrium is characterized by values of r2 > 0.2. Further disclosed is a method of predicting prognosis of a human individual experiencing symptoms associated with, or an individual diagnosed with, type 2 diabetes, the method comprising: obtaining sequence information about the human individual identifying at least one allele of at least one polymorphic marker selected from the group consisting of rs2334499, and markers in linkage disequilibrium therewith, wherein linkage disequilibrium is characterized by values of r2 > 0.2, wherein different alleles of the at least one polymorphic marker are associated with different susceptibilities to type 2 diabetes in humans, and predicting prognosis of type 2 diabetes of the human individual from the sequence data. Further disclosed are kits, computer programs and uses thereof for performing the methods as described above.
Patent NZ-598668-A (NZ)
Title: Methods for extraction and purification of gangliosides
Inventor: SCHNEIDER JAY S
IPC: C12P19/26
Filed: 2010-09-01
Abstract: Disclosed is a method of cell culture-based production of isolated, non-bovine and non-porcine GM1 ganglioside comprising the steps of: expanding, in a cell culture, GM1 producer cells derived from tissue that is non-bovine and non-porcine; expressing GM1 ganglioside in the GM1 producer cells of step (a); and isolating GM1 ganglioside expressed in step (b). Also disclosed is a method of preparing a pharmaceutical composition comprising isolated GM1 comprising the steps of: expanding, in a cell culture, GM1 producer cells derived from tissue that is non-bovine and non-porcine; expressing GM1 ganglioside in the GM1 producer cells of step (a); isolating GM1 ganglioside expressed in step (b); and combining the isolated GM1 of step (c) with a pharmaceutical excipient.
Patent NZ-600545-A (NZ)
Title: Condom wrapping
Inventor: DE WALEFFE XAVIER
IPC: A61F6/04
Filed: 2010-11-03
Abstract: 600545 A condom wrapping is disclosed. The wrapper includes two sheets (4, 6) of a flexible film welded at the edges so as to house a condom (12) in a rolled condition having an annular portion and a vessel. The sheet (4) opposite the vessel of the condom in the normal direction and opposite the normal unrolling direction of the condom is provided with a line of weakness (8) in the form of a circle having a diameter slightly smaller than that of the annular portion. The area of the sheet (4) defined by the line of weakness (8) is provided with a tab (10) arranged at the edge of the line (8) such as to be used as a wrapping gripping and opening means. Once open, the wrapping exposes the condom having the vessel oriented toward the outside, whereby the condom can be gripped by the vessel in the normal direction and is ready to be placed and unrolled.
Patent NZ-606364-A (NZ)
Title: Oligonucleotide chelate complexes
Inventor: VAILLANT ANDREW
IPC: C07H21/00
Filed: 2011-08-18
Abstract: Disclosed is a pharmaceutical composition comprising an oligonucleotide chelate complex comprising: at least two oligonucleotides linked intermolecularly by a divalent cation, wherein at least one oligonucleotide has at least one phosphorothioate linkage; and a pharmaceutically acceptable carrier.
Patent NZ-609482-A (NZ)
Title: Multiple coil flux pad
Inventor: JOHN TALBOT BOYS
IPC: H02J17/00
Filed: 2012-02-16
Abstract: Disclosed is a magnetic flux pad (7) for generating or receiving magnetic flux. The pad (7) includes at least three coils (2, 3, 3a) positioned such that the windings thereof are in substantially the same plane and are magnetically associated with a magnetically permeable material (5). Also included is a power supply or pickup controller operable to selectively conduct with two or more of the coils (2, 3, 3a) such that a magnetic field is produced or power is received by at least one of a plurality of pairs of the at least three coils (2, 3, 3a).
Patent NZ-622139-A (NZ)
Title: Methods and systems for forming boronic acids and intermediates thereof
Inventor: MENNING CATHERINE A
IPC: C07F5/02
Filed: 2012-09-14
Abstract: Disclosed is a method for forming the boronic acid herbicide 4-chloro-2-fluoro-7-methoxyphenylboronic acid (PBA), and intermediates thereof comprising: reacting 2-chloro-6-fluoroanisole (2,6-CFA) with an alkyllithium (e.g., butyllithium (BuLi)) to form the intermediate 6-chloro-2-fluoro-3-litihioanisole (Li-2,6-CFA) in a first reactor; and then continuously feeding said intermediate to a second reactor to react with trimethyl borate to form 4-chloro-2-fluoro-3-methoxyphenylboronate (PBA-diMe) which is subsequently converted to PBA by addition of KOH and acidification. The disclosed method provides a continuous formation of the boronic acid PBA and may reduce the amount of an undesired reactive benzyne species forming during the process which lowers reaction yield and poses a safety hazard. Also disclosed is a system for forming the boronic acid PBA.
Patent NZ-623939-A (NZ)
Title: Samidorphan (alks 33) in combination with opioid agonists
Inventor: DEAVER DANIEL
IPC: A61P25/24
Filed: 2012-12-17
Abstract: The disclosure relates to a composition comprising a pharmaceutically effective amount of an opioid agonist and Compound-1, also known as samidorphan or ALKS 33. The opioid agonist may be buprenorphine, morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine or tramadol. The composition may be used to treat a depressive disorder.
Patent NZ-628885-A (NZ)
Title: Automatic injection training device
Inventor: ANDERSON PHILIP D
IPC: G09B23/28
Filed: 2013-03-01
Abstract: An automatic injection training device (10) to simulate an automatic injection, the training device comprising: an elongate housing (12) extending along a longitudinal axis (L), the housing having a proximal end (16) and a distal end (14), the proximal end including an actuation member; a movable member disposed within the housing; a firing assembly disposed within the housing to actuate the movable member to simulate an automatic injection in response to an activation of the actuation member; and circuitry disposed within the housing to control an output of audio to train a user on an operational sequence of an actual automatic injection device using the training device. The circuitry comprises audio circuitry to output the audio; a nonvolatile storage device configured to control the output of the audio; and one or more sensors to sense a condition of the training device to provide an input to the programmable processing device to control an operation of the circuitry. The training device can provide audible instructions, which can be in different languages. The training device can be a self-contained and portable device that mimics a shape, size, and function of an actual automatic injection device without including a needle or any drug on board. The training device can be implemented to train a user on an operation and/or usage of an actual automatic injection device using embodiments of the automatic injection training devices so that a user can practice an autoinjection without injecting a therapeutic agent, such as a liquid drug, into a recipient.
Patent NZ-713051-A (NZ)
Title: S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
Inventor: COATS ANDREW J S
IPC: A61P25/28
Filed: 2014-03-14
Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
Patent NZ-716245-A (NZ)
Title: Fused benzoxazepinones as ion channel modulators
Inventor: CORKEY BRITTON KENNETH
IPC: C07D498/04
Filed: 2012-06-29
Abstract: The disclosure relates to compounds of formula IA that are sodium channel inhibitors, wherein Q, Cy, R2 – R4, R17, R10, m and n are as described in the specification. The disclosure also relates to their use the treatment of various disease states, including cardiovascular diseases and diabetes. The cardiovascular disease may be atrial and ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension or intermittent claudication.
Patent NZ-718867-A (NZ)
Title: N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
Inventor: SCHWAB WILFRIED
IPC: C07D417/12
Filed: 2012-09-26
Abstract: The present disclosure relates to an improved and shortened synthesis of N-[5- (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N- methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions.
Patent NZ-735904-A (NZ)
Title: Sterilisation of s-nitrosothiols
Inventor: REES DARYL
IPC: A61L2/00
Filed: 2016-03-21
Abstract: This invention provides a method of sterilising an S-nitrosothiol with ionising radiation, for example S- nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.